Abstract
Background: The immune status is usually hampered in patients of diabetes mellitus. The global pandemic of diabetes principally involves type 2 diabetes. In diabetic patients higher prevalence of hepatitis B virus infection is also noted that leads to more severe complications. This study was conducted to determine the immune responses to hepatitis B vaccine in type 2 diabetic patients.Methods: In this study 33 diabetic patients were included as experimental group and 34 non diabetic healthy persons were included as control group. All the participants were vaccinated with hepatitis B vaccine following 0, 1, 6 months schedule. The vaccine responses in diabetic and non diabetic group were compared depending on seromarkers (anti-HBs titer, IL-2 and IFN-?) following vaccination.Results: The mean value of anti-HBs titer was lower in diabetic group (357.81 mIU/ml) than non diabetic group (621.24 mIU/ml) but the difference was not significant (p>0.05), the mean value of IFN-? was lower in diabetic group (0.1480 IU/ml) than non diabetic group (0.2788 IU/ml) and here the difference was significant (p<0.05), the mean value of serum IL-2 level was also lower in diabetic group (0.2611IU/ml) than non diabetic group (0.3691 IU/ml) but the difference was not significant (p>0.05).Conclusion: The study revealed no statistically significant variation in anti-HBs and IL-2 but a diminished IFN-? level as the immune response in diabetic patients after HBV infection.J MEDICINE January 2016; 17 (1) : 8-11
Highlights
Both diabetes mellitus and hepatitis B virus infection are life threatening condition
Diabetes mellitus is related to increase the risk of developing chronic liver disease (CLD) and hepatocellular carcinoma (HCC)
The mean values of serum bilirubin were calculated as 0.527mg/dl and 0.489mg/dl for diabetic and non diabetic groups respectively
Summary
Both diabetes mellitus and hepatitis B virus infection are life threatening condition. In the Middle East and Indian sub-continent, an estimated 2% to 5% of the general population is chronically infected.[4] The prevalence of hepatitis B virus infection is higher in diabetic patients than in the healthy people.[5] Diabetes mellitus worsens the hepatic condition of hepatitis patients and increase the risk of complication.[6] Diabetes mellitus is related to increase the risk of developing chronic liver disease (CLD) and hepatocellular carcinoma (HCC). In diabetic patients higher prevalence of hepatitis B virus infection is noted that leads to more severe complications.This study was conducted to determine the immune responses to hepatitis B vaccine in type 2 diabetic patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
